oderna Therapeutics, a private biotech firm worth a reported $7.5 billion, lost its head of vaccines just after the company raised $500 million on the promise of advancing vaccines into late-stage trials.

Giuseppe Ciaramella, who joined Moderna in 2014, left the company in February for a job at an early-stage biotech startup, according to people familiar with the matter. As chief scientific officer of Moderna’s vaccine business, Ciaramella managed the company’s most-advanced projects, authoring the firm’s journal publications and shepherding seven investigational vaccines into clinical trials.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.